Bluebird Bio Shares Leap Premarket After FDA Clears Skysona
September 19 2022 - 6:38AM
Dow Jones News
By Colin Kellaher
Shares of bluebird bio Inc. rose sharply in premarket trading
Monday after the biotechnology company received accelerated U.S.
Food and Drug Administration approval for its Skysona gene therapy
for boys with a rare, fatal neurodegenerative disease.
The Somerville, Mass., company said the approval makes Skysona,
also known as eli-cel, the first therapy to slow the progression of
neurologic dysfunction in boys ages 4 through 17 with early, active
cerebral adrenoleukodystrophy.
Bluebird said it agreed to provide confirmatory long-term
clinical data to the FDA as a condition of the Skysona accelerated
approval, adding that it expects the drug will be available by the
end of the year.
Shares of bluebird, which closed Friday at $6.34, were recently
up nearly 16% to $7.33 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 19, 2022 06:23 ET (10:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024